Jpmorgan Chase & CO Lucid Diagnostics Inc. Transaction History
Jpmorgan Chase & CO
- $1.27 Trillion
- Q1 2025
A detailed history of Jpmorgan Chase & CO transactions in Lucid Diagnostics Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 46 shares of LUCD stock, worth $63. This represents 0.0% of its overall portfolio holdings.
Number of Shares
46
Previous 49
6.12%
Holding current value
$63
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding LUCD
# of Institutions
49Shares Held
9.45MCall Options Held
0Put Options Held
0-
Masters Capital Management LLC Atlanta, GA2.73MShares$3.79 Million0.21% of portfolio
-
Alyeska Investment Group, L.P. Chicago, IL1.89MShares$2.62 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA889KShares$1.24 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny459KShares$638,1000.0% of portfolio
-
Luminus Management LLC Houston, TX457KShares$634,7350.62% of portfolio
About Lucid Diagnostics Inc.
- Ticker LUCD
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 38,568,500
- Market Cap $53.6M
- Description
- Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarc...